|Bid||20.05 x 1800|
|Ask||21.89 x 500|
|Day's Range||19.98 - 20.33|
|52 Week Range||12.89 - 21.20|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
CNBC's Dominic Chu reports on Sarissa Capital Management's Alex Denner presenting his best investment ideas at Delivering Alpha.
Short interest is high for IRWD with between 15 and 20% of shares on loan. This means that investors who seek to profit from falling equity prices are currently targeting IRWD. The net inflows of $2.72 billion over the last one-month into ETFs that hold IRWD are not among the highest of the last year and have been slowing.
Ironwood (IRWD) initiates two phase III studies on its gastrointestinal candidate, IW-3718, to evaluate it in persistent gastroesophageal reflux disease.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Stocks hitting 52-week highs on June 7) Baxter International Inc (NYSE: BAX ) Bio-Rad Laboratories, ...
Ironwood Pharmaceuticals (IRWD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Ironwood Pharmaceuticals shareholders have rejected an attempt by activist investor Alex Denner to join the Cambridge drugmaker’s board, the company announced Thursday. Ironwood (Nasdaq: IRWD) said that shareholders at its annual meeting had voted to elect three independent directors who were up for re-election. The company had lobbied for that result in recent weeks and strongly opposed the election of Denner, who is known for orchestrating sales of local biotechs.
Commercial stage biopharma company Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD )'s Linzess, which it markets along with Allergan plc (NYSE: AGN ) in the U.S., is a major revenue earner for the company. ...
Ironwood Pharmaceuticals (IRWD) misses estimates on both counts in the first quarter. The company will be separated into two entities for better management.
Alex Denner, a protege of Carl Icahn, is known for orchestrating sales of companies in which he invests — including some local biotechs.
It will leave Ironwood as a traditional drugmaker focused on selling medications for irritable bowel syndrome, gout and reflux disease, with the goal of earning regular profits from the revenue growth. The other company will be more akin to a biotech aiming to bring to market promising but unproven drugs for rare disorders, such as sickle cell disease.
Ironwood Pharmaceuticals plans to separate into two entities next year. Activist investor Alex Denner of Sarissa Capital has invested in the company and is seeking a seat on its board. Ironwood Pharmaceuticals' IRWD stock rose Tuesday after the company said it plans to separate next year, immediately establishing profitability for its commercial entity and separating some of its pipeline assets into another unit.
The Cambridge, Massachusetts-based company said it had a loss of 29 cents per share. Losses, adjusted for one-time gains and costs, came to 27 cents per share. The drugmaker posted revenue of $69.2 million ...
The 730-employee company said that both businesses would be publicly traded and headquartered in Cambridge.
Short interest is moderately high for IRWD with between 10 and 15% of shares outstanding currently on loan. The net inflows of $122 million over the last one-month into ETFs that hold IRWD are among the lowest of the last year and appear to be slowing.
Ironwood Pharmaceuticals told shareholders Monday that it's learned biotech activist investor Alex Denner of Sarissa Capital is seeking to join its board.
Ironwood Pharmaceuticals Inc’s (NASDAQ:IRWD): Ironwood Pharmaceuticals, Inc., a commercial biotechnology company, engages in the research, development, and commercialization of human therapeutic products. The US$2.14B market-cap company announced a latest lossRead More...
Short interest is moderately high for IRWD with between 10 and 15% of shares outstanding currently on loan. The net inflows of $277 million over the last one-month into ETFs that hold IRWD are not among the highest of the last year and have been slowing.
Short interest is moderately high for IRWD with between 10 and 15% of shares outstanding currently on loan. Over the last one-month, outflows of investor capital in ETFs holding IRWD totaled $348 million.